Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

Atopic Dermatitis

What Is Atopic Dermatitis?

Patient Case Julien, 43-Year-Old Male

Patient Case: Julien Assessment and Confirmation of AD

Patient Case: Julien Identify Degree of Severity

Assessing Severity Clinical Trial and Practice Setting

Practical Engagement of the Patient

When Is Systemic Therapy Appropriate?

Begin Shared Decision-Making

Pharmacologic Therapies

Patient Case (cont)

Decision 'Tree' Is Dupilumab the Right Choice?

Defining Treatment Failure

Insurance Documentation

Managing Systemic Treatment

European vs US Access to Dupilumab

Management Approach to Pediatric Patients

Supporting Pediatric Patients Parental Education

Concluding Remarks

Abbreviations